The reporter noticed that since this year, a number of innovative Chinese pharmaceutical companies, such as Suzhou Yilian Biomedical Co., Ltd., Jiangsu Corning Jerry Biopharmaceutical Co., Ltd., and Yingen Biopharmaceutical Co., Ltd., have successively reached ADC external licensing deals. Industry insiders believe that with the continuous development of ADC technology, the R&D capabilities of innovative Chinese pharmaceutical companies are gradually gaining recognition in the international market, and multinational pharmaceutical companies' attention to China's ADC assets is also expanding from a single product to multiple R&D projects and technology platforms.

The reporter noticed that since this year, a number of innovative Chinese pharmaceutical companies, such as Suzhou Yilian Biomedical Co., Ltd., Jiangsu Corning Jerry Biopharmaceutical Co., Ltd., and Yingen Biopharmaceutical Co., Ltd., have successively reached ADC external licensing deals. Industry insiders believe that with the continuous development of ADC technology, the R&D capabilities of innovative Chinese pharmaceutical companies are gradually gaining recognition in the international market, and multinational pharmaceutical companies' attention to China's ADC assets is also expanding from a single product to multiple R&D projects and technology platforms.